Wednesday, January 31, 2024

Teva Pharm Profit Handily Beats Q4 Estimates, Sales Jump

(1/31, Steven Scheer, Reuters) ...Teva Pharmaceutical Industries reported sharply higher fourth-quarter profit, helped by higher sales and an upfront payment from Sanofi as part of its collaboration to develop a treatment for inflammatory bowel disease...Teva projected 2024 revenue of $15.7-$16.3 billion and adjusted EPS of $2.20-$2.50. In 2023, it posted revenue of $15.8 billion and adjusted EPS of $2.56... Full

Teva to Divest Active Pharmaceutical Ingredient Business

(1/31, Manas Mishra, Reuters) ...Teva Pharmaceutical Industries will divest its active pharmaceutical ingredient unit to focus on its core business, the world's largest generic drugs maker said on Wednesday. The API unit, which brought in revenue of $1.05 billion in 2022, makes pharmaceutical ingredients that are used in both generic and branded medicines, and serves over 1,000 clients globally... Full

Teva to Sell API Activity

(1/31, Maya Levin, Globes) ...Teva said it expects the sale to be completed by the first half of 2025, "subject to reaching a satisfactory agreement on transaction terms with a prospective purchaser, the successful satisfaction of closing conditions, and the approval of an agreed transaction by Teva's Board of Directors." Teva said that the sale of TAPI will allow Teva, "To maximize current and potential revenue streams, focusing on capital reallocation towards growth and innovation, and to better serve patients.”... Full

Teva Plans to Divest API Business as Part of Strategic Pivot

(1/31, Adriano Marchese, Dow Jones) ...Teva Pharmaceutical Industries plans to divest its active-pharmaceutical ingredient business as it looks to pursue new growth opportunities..."The divestiture of TAPI will ... allow us to increase the focus on our core business, continue to invest in our growth drivers, accelerate our innovative and biosimilar pipeline, and position our generics portfolio and pipeline to drive growth for the future," said Chief Executive Richard Francis... Sub. Req'd

Teva Plans to Divest its Active-Pharmaceutical Ingredient Business

(1/31, The Fly) ...The intent to divest "TAPI" will allow Teva to maximize current and potential revenue streams, focusing on capital reallocation towards growth and innovation, and to better serve patients. The intended divestiture is expected to create additional value for Teva's shareholders and other stakeholders by allowing Teva to better address distinct, growing markets with Teva's leading product offerings... Full

Teva to Divest API Unit to Focus On Core Business Strengths

(1/31, Preeti Singh, Seeking Alpha) ...Teva plans to divest its active-pharmaceutical ingredient business as part of its Pivot to Growth strategy to focus on its core business strengths... Full

Senator Turns Up Heat On Inhaler Manufacturers to Remove Improperly Listed Orange Book Patents

(1/30, Lia DeGroot, Endpoints News) ...Sen. Tammy Baldwin (D-WI) is the latest lawmaker to call on inhaler manufacturers to remove what the FTC has deemed improperly listed patents from the Orange Book as policymakers continue to pressure pharma companies for misusing the patent system to fend off competition. In letters to AstraZeneca, Boehringer Ingelheim, GSK and Teva on Tuesday, Baldwin urged the companies to remove patents that the FTC identified in November as being improperly listed and staving off generic and biosimilar competition... Full

Teva Pharmaceuticals: Driving the Sustainability Agenda from Treasury

(1/30, EuroFinance) ...Speaking at the 2023 International Treasury Management conference, David Hanhart, EMEA Treasurer at Teva Pharmaceuticals, shared his insights on the impact that the transaction has had on Teva's ESG journey and the challenges and opportunities the treasury team faced in driving sustainable financing initiatives... Full

India's Sun Pharma Beats Q3 Profit View On Strong Domestic, US Sales

(1/31, Kashish Tandon and Rishika Sadam, Reuters) ...India's largest drugmaker Sun Pharmaceutical Industries reported third-quarter profit above estimates on Wednesday, driven by strong sales in the key domestic and U.S. markets. The company reported a consolidated profit after tax of 25.24 billion rupees ($304 million) for the quarter ended Dec. 31, beating analysts' estimate of 24.17 billion rupees as per LSEG data... Full

Dr. Reddy's Q3FY24 Results: Pharma Major to Focus On Scaling Up its Consumer Health Segment; To Launch IBS Management Platform Soon

(1/31, Sushmita Panda, Financial Express) ...Pharma major Dr. Reddy's Laboratories on Tuesday reported its consolidated financial results for the quarter and nine months ended December 31, 2023. According to the company's statement, its third quarter profit for the financial year 2023-24 at Rs 1380.90 crore, up 11 per cent in comparison to Rs 1243.90 crore during the corresponding quarter of previous year...On plans for the chronic disease segment, M. V. Ramana, CEO, Branded Markets (India & Emerging Markets), Dr. Reddy's Laboratories told Financial Express.com that they are working on three levels for the growth of the business... Full

Novartis Misses Q4 Profit Expectations As Costs Disappoint

(1/31, Ludwig Burger, Reuters) ...Novartis reported a 6% gain in adjusted net income on Wednesday that fell short of the market view, as corporate expenses surpassed expectations built up by a recent cost-cutting drive...The shares dropped 4% at 0815 GMT, tempering gains of 9% so far this year, as analysts pointed to higher-than-expected costs and some disappointment over the 2024 goal. Terence McManus, a fund manager at Switzerland's Bellevue Asset Management, said quarterly results were slightly weak, but that likely reflected money spent on drug launches... Full

GSK Sees Strong Growth as Haleon Split and Vaccine Drive Pays Off

(1/31, Eva Mathews, Reuters) ...GSK beat market estimates for fourth-quarter results on Wednesday, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs pipeline, underscoring the benefits of its consumer health unit spin-off...CEO Emma Walmsley's strategy has been centred around sharpening GSK's focus on vaccines and infectious diseases, and shifting its HIV focus to long-acting treatment and prevention therapies, amid a series of upcoming patent expiries and declining revenue from current bestsellers... Full

Pfizer Posts Surprise 4th Quarter Profit, But Key Products Miss On Sales

(1/30, Michael Erman and Bhanvi Satija, Reuters) ..."This will be a year of execution. We have assembled a team that I hand-picked, that I believe are the absolutely right leaders to" put Pfizer's growth plan into place, Chief Executive Albert Bourla said on a call with investors. "Our abilities to execute across all our operation are proven," Bourla said in an interview, pointing to the company's success developing its COVID-19 vaccine and treatment. Pfizer has forecast 2024 revenue in a range that is flat to up 5%... Full

Three Burning 2024 Questions for Pfizer: What to Do in Weight Loss, The Hunt for Megablockbusters, and Integrating the Deals

(1/30, Andrew Dunn, Endpoints News) ...Pfizer has declared 2024 to be a year of execution. It's likely to be judged on whether it can also be a year when the stock turned around, and investors turned into believers of its post-Covid strategy...On Tuesday, Bourla voiced confidence they've achieved $20 billion of that goal, yet stopped short of doubling down on achieving that final $5 billion.) Instead, its priorities are protecting its dividend and bringing down debt levels. The company is in the middle of a major cost-cutting initiative that has taken $2 billion out of the business in 2023 and looks to get an additional $2 billion done this year... Full

Pfizer Korea and Hanlim MS Sign Co-Marketing Agreement for Xeljanz

(1/31, Lee Han-soo, Korea Biomedical Review) ...Pfizer Korea and Hanlim MS said they entered into a co-marketing agreement for the drug Xeljanz (ingredient: tofacitinib citrate), a drug used in the treatment of various autoimmune diseases. This collaboration aims to expand the availability and benefits of Xeljanz to a wider patient demographic through combined efforts in distribution and marketing... Full

Sandoz Launches Biosimilar for Multiple Sclerosis in Germany

(1/31, Sushmita Panda, Financial Express) ...Sandoz, a key player in generic and biosimilar medicines, on Wednesday announced the launch of Tyruko (natalizumab) in Germany from February 1. Developed by Polpharma Biologics, Tyruko is the first and only biosimilar to treat RRMS, the company said in a statement. According to the biosimilar maker, Tyruko is indicated as a single disease-modifying therapy in adults with highly active RRMS. This is the same indication as approved by the European Commission for reference medicine Tysabri... Full

Fresenius Kabi Introduces Posaconazole Injection to Prevent and Treat Fungal Infections

(1/31, Pharmabiz.com) ...Fresenius Kabi announced it has introduced posaconazole injection, a generic substitute for Noxafil, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system. Now available in the US, posaconazole injection is the newest addition to Fresenius Kabi's portfolio of more than 30 anti-infective molecules... Full

Gilead's Kite Wins FDA Nod for New CAR-T Manufacturing Process to Speed Up Yescarta Turnaround

(1/30, Angus Liu, Fierce Pharma) ...The FDA has approved a new manufacturing process change for Yescarta, Gilead's Kite Pharma unit said Tuesday. The approval allows the company to shorten the CAR-T cell manufacturing time for Yescarta from an average of seven days to five days, Chris McDonald, Kite's head of technical operations, told Fierce Pharma. Thanks to this shortened production timeline, Kite will be able to reduce the median turnaround time for Yescarta... Full

AION Labs Launches New Startup Using AI to Discover Molecular Glue Therapies

(1/30, Jessica Hagen, MobiHealthNews) ...Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup, TenAces. TenAces will utilize AI, integrating biology and machine learning algorithms, to discover molecular glue therapies to enhance targeted protein degradation...AION Labs was built under a government tender with the support of the Israeli government via the Israel Innovation Authority. The company includes pharma giants AstraZeneca, Merck, Pfizer and Teva... Full

AI Brings Speed to Drug Development But Not Yet Clinical Success

(1/31, Naomi Kresge and Ian King, Bloomberg) ...In mid-January, Genentech started recruiting 200 patients to test whether one of its experimental drugs can tame ulcerative colitis, a painful, incurable type of inflammatory bowel disease. Until then, the compound had only been given during experiments to treat lung and skin disorders. Deciding whether to shift a drug for use against a different disease than originally intended often takes years of painstaking lab work, but the California biotech did it in just nine months. The difference: artificial intelligence, which the company says helped its researchers scan millions of possibilities to confirm the drug could be useful against diseases affecting the cells of the colon... Sub. Req'd

New Drug Shown to Relieve Pain Without Getting Patients Addicted

(1/30, Jennifer Calfas, The Wall Street Journal) ...Vertex Pharmaceuticals on Tuesday reported positive study results for its closely watched non-opioid painkiller. The drug lowered the moderate-to-severe acute pain reported by study volunteers, a sign it could be the first in a new class of painkiller to be approved for use. But the experimental medicine is more likely to provide an alternative to opioids, rather than supplant them, because it didn't work better than a widely used opioid drug sold under the brand name Vicodin... Sub. Req'd

Boehringer Ingelheim Korea Initiates Voluntary Recall for COPD and Asthma Treatment

(1/31, Lee Han-soo, Korea Biomedical Review) ...Boehringer Ingelheim Korea said it has commenced a voluntary recall of select batches for Spiriva Respimat (ingredient: tiotropium bromide hydrate), its chronic obstructive pulmonary disease and asthma medication...The decision for the recall was made following the discovery of defects in the medication indicator of the cartridge within the product. The product comprises a 4.5 ml cartridge and an inhaler, with the drug indicator allowing users to ascertain when cartridge replacement is needed... Full

Exclusive: Eli Lilly Supplied Schizophrenia Drug to Uncertified Healthcare Providers, Form 483 Shows

(1/30, Anna Brown, Endpoints News) ...Eli Lilly shipped its schizophrenia drug to uncertified pharmacies and was not adhering to established safety procedures, the FDA found after a September inspection at the company's corporate offices in Indiana. The agency noted five deficiencies involving Zyprexa Relprevv, in which the company did not follow the approved Risk Evaluation and Mitigation Strategy, a program for drugs with serious safety concerns, according to a Form 483 obtained by Endpoints News through a FOIA request... Full

72% of Pharmacy Technicians Surveyed Report Workflow Affected by Drug Shortages

(1/30, Ashley Gallagher, Pharmacy Times) ...In approximately 96% of certified pharmacy technicians who responded to a survey said that their pharmacy had drug shortages, according to an analysis conducted by the Pharmacy Technician Certification Board...The most common drugs mentioned by pharmacy technicians in the survey included amphetamine and dextroamphetamine (Adderall; Teva Pharmaceuticals); bupivacaine (Exparel; Pacira Biosciences, Inc); the chemotherapy drugs carboplatin and cisplatin; and lidocaine... Full

Humira Biosimilar Landscape: Still Waiting

(1/30, The Biosimilars Council) ...A year later—and despite competition from 14 lower-cost, FDA approved biosimilar versions—it is disappointingly clear how many commercial, employer and government payers and their PBMs have been slow to adopt these medications. New research from the Biosimilars Council suggests that this slower-than-expected adoption may continue through 2024... Full

Generics Bulletin Explains: One Year On, US Humira Biosimilars Continue To Struggle For Share

(1/31, David Wallace, Generics Bulletin) ...A year to the day since the launch of the first US rival to Humira, adalimumab biosimilars are still struggling to gain a significant foothold in the market. Generics Bulletin looks at the reasons why. This time last year, all eyes were on the US biosimilars market, as the off-patent industry's biggest ever single loss-of-exclusivity opportunity in history loomed... Global Sub. Full

The FTC Is Attacking Drugmakers' ‘Patent Thickets'

(1/31, Elisabeth Rosenthal, KFF Health News) ...The Federal Trade Commission has challenged the validity of over 100 drug product patents, focusing on devices used to deliver medicines, like inhalers and autoinjectors, in an effort to increase competition and potentially lower some prices...President Joe Biden has instructed his Federal Trade Commission to be more aggressive in reining in the pharmaceutical industry. Under its chairperson, Lina Khan, the agency is aggressively testing the limits of its powers in pursuit of that goal. The targeted patents cover devices that propel medicines for asthma and emphysema into the lungs or inject epinephrine to treat a severe allergic attack... Full

Bernie's Anti-Pharma Crusade Is Not In Patients' Interests

(1/30, Sally Pipes, Forbes) ...Next week, the Senate Health, Education, Labor, and Pensions Committee will convene to hear testimony from the CEOs of Johnson & Johnson, Merck, and Bristol Myers Squibb on the prices of their drugs. The executives agreed to testify after the committee's chair, Vermont socialist Sen. Bernie Sanders, I-Vt., threatened to issue subpoenas compelling them to appear. He's relishing the chance to scold them. "Why does the United States pay, by far, the highest prices in the world for prescription drugs?" he asked in a letter last fall to the CEOs... Full

Big Pharma Will Have to Answer to the American People

(1/31, Sen. Bernie Sanders, FOX News) ...As the chairman of the Senate Committee on Health, Education, Labor and Pensions, one of my top priorities is to substantially reduce the price of prescription drugs in America. One of the ways to do that is to hold the chief executives of some of the largest pharmaceutical companies in our country accountable for their actions. That is why I have invited Robert Davis, the CEO of Merck; Joaquin Duato, the CEO of Johnson & Johnson; and Chris Boerner, the CEO of Bristol Myers Squibb, to a hearing to discuss what they are doing to lower drug prices in America... Full

Medicare to Kick Off First Drug Price Negotiations, and it Could Get Heated

(1/30, Berkeley Lovelace Jr., NBC News) ..."I expect negotiations to be intense," said Lawrence Gostin, director of the O'Neill Institute for National and Global Health Law at Georgetown University. "Big Pharma is likely to dig in its heels and use a variety of strategies, including fierce negotiations." By Thursday, the CMS is expected to send its first pricing offer to each drug company that makes the 10 selected drugs, said Juliette Cubanski, a Medicare expert with KFF, a nonpartisan group that studies health policy issues... Full

Dose of Reality: Big Pharma's Egregious Pricing Practices and Anti-Competitive Tactics Drive Higher Health Care Costs

(1/30, The Campaign For Sustainable Rx Pricing) ...Tomorrow, the U.S. House Committee on Energy and Commerce Health Subcommittee is scheduled to hold a hearing to discuss health care spending in the United States. Ahead of the hearing on this important topic, get a Dose of Reality on Big Pharma's egregious pricing practices and anti-competitive tactics that are the root cause of high prescription drug prices, and that impose massive costs on patients, taxpayers, and the U.S. health care system... Full

DOJ Rejects Novo Nordisk's Claim CMS Illegally Counts 6 Drugs As 1 Under IRA

(1/30, Gabrielle Wanneh, InsideHealthPolicy) ...In a brief filed with a federal district court in Delaware Friday (Jan. 26), the government stood its ground against claims by Novo Nordisk that CMS is imposing Medicare drug price negotiation on more drugs than Congress authorized in the Inflation Reduction Act (IRA). The brief comes as CMS is expected to submit its first offer of lower prices for 10 selected Part D drugs by Thursday (Feb. 1), and as nine active lawsuits remain in play challenging the new price-setting authority granted to the agency... Sub. Req'd

As AstraZeneca Gears Up for Courtroom Showdown Over IRA, Novo's Case Faces Separate HHS Rebuke

(1/30, Fraiser Kansteiner, Fierce Pharma) ...Wednesday, lawyers for AstraZeneca are set to engage in oral arguments against the U.S. Department of Justice in a federal court, according to a September court order and a new report from Bloomberg Law. The British drugmaker aims to challenge the legality of the drug pricing provisions put in place under the IRA, which will allow Medicare to haggle over the prices of some of the costliest drugs it covers starting in 2026...While Novo argues that the price-negotiation program in the IRA hampers its First and Fifth Amendment rights, HHS disagrees. The agency claims Novo's constitutional rights aren't infringed because drugmakers aren't legally compelled to participate in the Medicare program... Full

AstraZeneca's Day in Court On Drug Price Negotiations

(1/30, Lauren Gardner, Politico) ...The Justice Department heads to federal court in the state where President Joe Biden resides this week to defend its Medicare drug price negotiations program. Oral arguments in AstraZeneca's case in the U.S. District Court for the District of Delaware will be the first concerning the merits of the pharmaceutical industry's efforts challenging the program's constitutionality. A September hearing in the U.S. Chamber of Commerce's challenge to the law in an Ohio federal district courtroom concerned whether the negotiations should be halted while the litigation plays out; that bid was denied... Full

Medicare Drug Negotiations, Medicare Advantage In Spotlight This Week

(1/29, InsideHealthPolicy) ...The fate of Medicare drug price negotiations will come closer into view this week as the first of many oral arguments in the drug industry's challenge to the Inflation Reduction Act are set for Wednesday -- one day ahead of CMS' deadline for setting the initial offer of a maximum fair price to the manufacturers of the 10 selected Medicare drugs. Stakeholders are also preparing for the release of the 2025 advanced notice of MA payment changes slated for Thursday... Sub. Req'd

ICER Would Contribute to Medicare Price Negotiations Under One Condition, New President Says

(1/30, Angus Liu, Fierce Pharma) ...With the Inflation Reduction Act's Medicare price negotiations moving ahead rapidly, one party not officially involved in the talks is the Institute for Clinical and Economic Review...Still, one key condition would need to be met for that to happen, the cost watchdog's new president said in a recent interview. "I think we would need some direction from [the Centers for Medicare & Medicaid Services] that they wanted the drug price negotiation program to be about value, and not just about a lower price," ICER's president, Sarah Emond, told Fierce Pharma on the sidelines of the 2024 J.P. Morgan Healthcare Conference... Full

Guest Opinion: A New Year's Resolution – Lower Drug Prices

(1/30, Patricia Kelmar, Daily Herald) ...Each January, many Utahns and other Americans resolve to take steps to improve their health over the coming year. Why not also ask Congress to make a resolution that can help us all: voting to reform our prescription drug pricing system? While many of the world's most important medical breakthroughs happen in U.S. labs, medicines developed there often cost too much for patients... Full

BPC Urges FDA, CMS Collaboration To Streamline Coverage, Improve RWE

(1/30, Maaisha Osman, InsideHealthPolicy) ...The non-profit group specifically calls for FDA to systematically share preapproval information with CMS, including a list of drugs being considered for accelerated approvals, the schedule of upcoming advisory committee meetings, and a list of products expected to be approved in the following three months. And CMS should share real-world evidence data it gathers from the Agency for Healthcare Research and Quality with FDA, BPC adds... Sub. Req'd

Experts Critique Flawed System for Monitoring Drugs' Side Effects in Wake of Asthma Drug Report

(1/31, Theresa Gaffney, STAT Plus) ...After a drug enters the market, it's up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren't always aware of the risks... Sub. Req'd

FDA Releases Final Label Revision And TA ANDA Amendment Guidances

(1/30, Urte Fultinaviciute, Generics Bulletin) ...The US Food and Drug Administration has released two final guidance documents in a bid to clarify the label revision and amendment submissions to tentatively approved abbreviated new drug applications. The two guidances, which were issued last week, are a part of the Drug Competition Action Plan, which aims to "improve the efficiency of the generic drug development, review, and approval process", in return leading to expanded access to "safe, high-quality, effective generic medicines."... Global Sub. Full

Some Lawmakers Want NY to Manufacture Prescription Drugs, Lower Costs

(1/30, Jamie DeLine, Rochester First) ...Majority Leader Andrea Stewart-Cousins announced the New York State Senate is advancing a package of legislation to make prescriptions like, insulin, less expensive for New Yorkers..."What this bill will do is authorize the state to partner with private companies to actually produce generic drugs, particularly insulin," explained Senator Gustavo Rivera, the bill's sponsor. Affordable insulin is a priority for Governor Kathy Hochul too. In her executive budget, she proposed banning copays for the drug on some insurance plans... Full

NY Senate Passes Prescription Drug Affordability Package

(1/30, Austin C. Jefferson, City & State New York) ...Democratic state senators passed a legislative package Tuesday aimed at making prescription medications and health care more affordable. State Senate Majority Leader Andrea Stewart-Cousins was joined by state Sens. Gustavo Rivera, Neil Breslin, Nathalia Fernandez, Zellnor Myrie and James Skoufis as they announced the legislation. "Started with insulin, we're moving along the line, all to address the great affordability crisis that's spreading all over New York," Health Committee Chair Rivera said... Full

AAM And Medicines For Europe Urge Transatlantic Framework For Complex Generics

(1/30, Urte Fultinaviciute, Generics Bulletin) ...European and US generics and biosimilars organizations Medicines for Europe and the Association for Accessible Medicines have released a joint statement urging a common EU and US development program for complex generics, as the transatlantic political body EU-US Trade and Technology Council gathered to discuss key trade and economic issues in Washington DC on January 30. In the statement released ahead of the 5th TTC meeting, AAM and Medicines for Europe called for both regions to enable a regulatory framework that will allow a Single Development Program for complex generic medicines... Global Sub. Full

New Critical Medicines Alliance Says Join Us In Tackling Critical Medicines Shortages

(1/30, Neena Brizmohun, Pink Sheet) ...Moves to set up a "Critical Medicines Alliance" in the EU to tackle the problem of critical medicines shortages by changing the way the bloc produces and procures drugs and reinforces its security of supply have stepped up a gear. Drug companies, national authorities and many other pharmaceutical sector stakeholders have been invited to express their interest in joining the alliance, which will initially last for five years and is due to start its work this spring... Sub. Req'd

EU's Innovative Drug Approval Tally Shows Sharp Decline

(1/31, Ian Schofield, Pink Sheet) ...The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus. In 2023, the European Commission approved 36 medicines containing a new active substance, the lowest number since 2019 when just 28 NAS-containing drugs gained an EU-wide marketing authorization. Among the 36 products were 16 cancer drugs and one gene therapy... Sub. Req'd

Experts Outline Challenges of Combination Products in Europe

(1/30, Denise Fulton, Regulatory Focus) ...Combination products are increasingly important, increasingly complex and are increasing the pressure on the European regulatory network, according to Thomas Wejs Møller, senior director for regulatory affairs – devices at Novo Nordisk... Full

India Could Help Break China's Hold on U.S. Drug Supply Chains | Opinion

(1/30, Rahul Tiwari, Newsweek) ...In recent years, increasing geopolitical tensions, trade decoupling, and the coronavirus pandemic have revealed the vulnerability of America's pharmaceutical supply chains. It is increasingly evident that the United States' dependence on China is a significant risk, especially for obtaining vital medications. Addressing this risky dependency is of utmost importance. Fortunately, India—an increasingly important partner and friend to the United States—is positioned to help. Tapping into this partnership and the burgeoning potential of India's pharmaceutical manufacturing sector could be the key to alleviating this critical issue... Full

Note: Article links may expire over time or require a free registration. All news articles are the property of their respective publishers and copyright holders. [contextual emphasis added].

Teva global subscription access: Registration is required to access FirstWord and Generics Bulletin. Click on the links below to register. If you have any questions or issues with access, contact InfoNOW or visit InfoNOW's Industry News page for more details regarding these subscriptions.

                                                         

FirstWord Pharma Plus: Enter your work email address on the Registration page along with your contact information in order to receive access.

  

Generics Bulletin by Informa:

•      Registration: Click on "Sign In" (link on the upper right side of the page). Enter your work email address in the "username" box and press the "Tab" button on your keyboard or click out of the box. You will then be automatically logged into the Informa news resource (no password required). You may be redirected to the Account Settings page to update your contact information.                                

•       Subsequent Access: If you're not automatically logged in, click on "Sign In" (link on the upper right side of the page). Enter your work email address. You will be automatically logged in (no password is required).

•      Note: You must be on the Teva Network (in a Teva location or connected via VPN) in order to access the Informa news resources. You can toggle between the Informa news resources by clicking the news resource on the top.